Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Copaxone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | DRUG | 250mcg administered s.c. every other day |
| Copaxone | DRUG | 20 mg administered s.c. once daily. |
Inclusion Criteria: * Female and male patients * Aged 18-55 years * Diagnosis of RRMS (Relapsing-Remitting Multiple Sclerosis), EDSS score of 0 to 5.0 * Treatment-naive to IFNB or Copaxone Exclusion Criteria: * Neurological progression at disease onset or between relapses * Serious or acute heart...
Copaxone is used for the treatment of relapsing-remitting multiple sclerosis, a form of MS characterized by flare-ups followed by periods of remission. It is being developed for this neurological condition and has been studied in a Phase 3 clinical trial.
Copaxone is being developed by Bayer AG, a company traded under the ticker symbol BAYRY. The drug is being studied for the treatment of relapsing-remitting multiple sclerosis and has completed a Phase 3 clinical trial.
Copaxone is in Phase 3 clinical development for relapsing-remitting multiple sclerosis. It has completed one Phase 3 trial, and it remains an investigational drug, meaning it has not yet been approved for use.
Copaxone has been studied in one completed Phase 3 clinical trial, identified as NCT00099502. This trial, known as BEYOND, enrolled 2,244 participants with relapsing-remitting multiple sclerosis and was conducted across multiple countries.
Copaxone is not the same as Betaferon. The clinical trial NCT00099502, which studied Copaxone, is titled BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis Patients, but the trial compared different treatments, and Copaxone is a distinct drug.